Alzamend Neuro is trading 17.04% higher at $1.58, with no clear October 12 catalyst identified. - That compares with the October 9 close of $1.34. - A Zacks upgrade to Rank #2 (Buy) was published October 8, but no evidence links it directly to the pre-market move. The company’s news page lists its latest release as September 16. - Major indices are modestly higher, but that does not establish a broad-market explanation.